Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GridAI Technologies Corp.ENTO · Entity 7534 | Chief Financial Officer | January 06, 2025 | January 08, 2025 |
| KIORA PHARMACEUTICALS INCKPRX · Entity 7940 | Chief Financial Officer | February 10, 2022 | February 11, 2022 |
| Onconetix, Inc.ONCO · Entity 8471 | Director | December 05, 2025 | December 12, 2025 |
| SS Innovations International, Inc.SSII · Entity 5246 | CFO | August 03, 2026 | August 04, 2026 |
| Vicarious Surgical Inc.RBOT · Entity 8714 | Chief Financial Officer | April 01, 2025 | April 11, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GridAI Technologies Corp.
Report date January 06, 2025 · Filed January 08, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 17,287 |
Reported balance
After 2025-01-06 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-01-06 · Sale · Disposed 727 · Balance 17,287 F1: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units ("RSUs"). The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2: Includes unvested RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units ("RSUs"). The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
F2: Includes unvested RSUs.
KIORA PHARMACEUTICALS INC
Report date February 10, 2022 · Filed February 11, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 22,746 |
Reported balance
After 2022-02-10 transaction · row 1
1 source rowRow 1 · 2022-02-10 · Tax withholding · Disposed 108 · Balance 22,746 F1: Sale of shares to cover taxes due on restricted stock that vested on 02/01/2022. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.69 to $0.70, inclusive. The reporting person hereby undertakes to provide to Kiora Pharmaceuticals, Inc., any security holder of Kiora Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: Sale of shares to cover taxes due on restricted stock that vested on 02/01/2022.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.69 to $0.70, inclusive. The reporting person hereby undertakes to provide to Kiora Pharmaceuticals, Inc., any security holder of Kiora Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
Onconetix, Inc.
Report date December 05, 2025 · Filed December 12, 2025
This filing explicitly reported no securities owned.
SS Innovations International, Inc.
Report date August 03, 2026 · Filed August 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $3.95 · Expires 2031-08-03 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-08-03 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: Represents options to purchase 750,000 shares of Common Stock (the "Options") granted to the Reporting Person on August 3, 2026 under the Issuer's 2026 Incentive Stock Plan (the "Incentive Plan"). The Options vest as follows: 250,000 shares vest on August 3, 2027 (the first anniversary of the grant date); thereafter, the Options vest in twenty-three (23) equal monthly installments of 20,833 shares each, with a final monthly installment of 20,841 shares, in each case subject to the Reporting Person's continued employment with the Issuer and the other terms and conditions of the Incentive Plan. In the event of a Change in Control (as defined in the Reporting Person's Employment Agreement) occurring prior to the full vesting of the Options, and provided the Reporting Person remains employed by the Issuer at such time, any unvested portion of the Options shall immediately vest in full. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents options to purchase 750,000 shares of Common Stock (the "Options") granted to the Reporting Person on August 3, 2026 under the Issuer's 2026 Incentive Stock Plan (the "Incentive Plan"). The Options vest as follows: 250,000 shares vest on August 3, 2027 (the first anniversary of the grant date); thereafter, the Options vest in twenty-three (23) equal monthly installments of 20,833 shares each, with a final monthly installment of 20,841 shares, in each case subject to the Reporting Person's continued employment with the Issuer and the other terms and conditions of the Incentive Plan. In the event of a Change in Control (as defined in the Reporting Person's Employment Agreement) occurring prior to the full vesting of the Options, and provided the Reporting Person remains employed by the Issuer at such time, any unvested portion of the Options shall immediately vest in full.
Vicarious Surgical Inc.
Report date April 01, 2025 · Filed April 11, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.32 · Expires 2036-04-10 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2025-04-01 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: The shares underlying this option vest as to 25% of the award on April 11, 2026, with the remainder vesting in equal monthly installments over the following 36 months, subject to the Reporting Person's continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option vest as to 25% of the award on April 11, 2026, with the remainder vesting in equal monthly installments over the following 36 months, subject to the Reporting Person's continued service through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 06, 2025 Filed Jan 8, 2025 21:23 UTC | GridAI Technologies Corp. ENTO · Entity 7534 | SaleCommon Stock | 727 | $0.64 | $465.28 |
DisclosureSEC source: 0001104659-25-002042 · tm252282-1_4seq1.xml · nonDerivative · entry 1 Romano Sarah · CIK 0001697536 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,287 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units ("RSUs"). The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · balance_after: Includes unvested RSUs. Read SEC document |
| October 09, 2024 Filed Oct 10, 2024 21:00 UTC | GridAI Technologies Corp. ENTO · Entity 7534 | SaleCommon Stock | 476 | $0.45 | $212.30 |
DisclosureSEC source: 0001104659-24-107747 · tm2425931-1_4seq1.xml · nonDerivative · entry 1 Romano Sarah · CIK 0001697536 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,014 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units ("RSUs"). The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · balance_after: Includes unvested RSUs. Read SEC document |
| July 02, 2024 Filed Jul 3, 2024 18:34 UTC | GridAI Technologies Corp. ENTO · Entity 7534 | SaleCommon Stock | 621 | $1.07 | $664.47 |
DisclosureSEC source: 0001104659-24-077714 · tm2418821-2_4seq1.xml · nonDerivative · entry 1 Romano Sarah · CIK 0001697536 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,490 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units ("RSUs"). The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $1.05 - $1.16, inclusive. The Reporting Person undertakes to provide Entero Therapeutics, Inc. ("Entero"), any security holder of Entero, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F3 · balance_after: Includes unvested RSUs. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 21:13 UTC | GridAI Technologies Corp. FWBI · Entity 7534 | SaleCommon Stock | 75 | $4.23 | $317.21 |
DisclosureSEC source: 0001104659-24-043154 · tm2411006-2_4seq1.xml · nonDerivative · entry 1 Romano Sarah · CIK 0001697536 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,111 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units ("RSUs"). The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · balance_after: Includes unvested RSUs. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 20:10 UTC | GridAI Technologies Corp. FWBI · Entity 7534 | SaleCommon Stock | 1,120 | $4.96 | $5,555.20 |
DisclosureSEC source: 0001104659-24-036138 · tm249257-1_4seq1.xml · nonDerivative · entry 1 Romano Sarah · CIK 0001697536 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,186 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units ("RSUs"). The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $4.90 - $5.175, inclusive. The Reporting Person undertakes to provide First Wave BioPharma, Inc. ("First Wave"), any security holder of First Wave, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F3 · balance_after: Includes unvested RSUs. Read SEC document |
| January 12, 2024 Filed Jan 17, 2024 21:02 UTC | GridAI Technologies Corp. FWBI · Entity 7534 | SaleCommon Stock | 98 | $4.20 | $411.60 |
DisclosureSEC source: 0001104659-24-004460 · tm243514-2_4seq1.xml · nonDerivative · entry 1 Romano Sarah · CIK 0001697536 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,306 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units ("RSUs"). The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · balance_after: Includes unvested RSUs. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 00:54 UTC | GridAI Technologies Corp. FWBI · Entity 7534 | GrantCommon Stock | 7,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-001025 · tm241923-2_4seq1.xml · nonDerivative · entry 2 Romano Sarah · CIK 0001697536 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,404 F2 · shares: On January 2, 2024, the Reporting Person was granted 7,000 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units vest quarterly for one year with 25% vesting quarterly beginning April 1, 2024. F3 · balance_after: Includes unvested RSUs. Read SEC document |
| December 29, 2023 Filed Jan 4, 2024 00:54 UTC | GridAI Technologies Corp. FWBI · Entity 7534 | GrantCommon Stock | 12,614 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-001025 · tm241923-2_4seq1.xml · nonDerivative · entry 1 Romano Sarah · CIK 0001697536 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,404 F1 · shares: On December 29, 2023, the Reporting Person was granted 12,614 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units vest upon closing of the Issuer's proposed acquisition of ImmunogenX, Inc. F3 · balance_after: Includes unvested RSUs. Read SEC document |
| October 04, 2023 Filed Oct 6, 2023 20:05 UTC | GridAI Technologies Corp. FWBI · Entity 7534 | SaleCommon Stock | 1,676 | $0.29 | $486.04 |
DisclosureSEC source: 0001104659-23-107483 · tm2327991-2_4seq1.xml · nonDerivative · entry 1 Romano Sarah · CIK 0001697536 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,800 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units ("RSUs"). The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.291 to $0.293. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes unvested RSUs. Read SEC document |
| July 03, 2023 Filed Jul 5, 2023 20:28 UTC | GridAI Technologies Corp. FWBI · Entity 7534 | SaleCommon Stock | 1,977 | $1.54 | $3,044.58 |
DisclosureSEC source: 0001104659-23-078145 · tm2320603-2_4seq1.xml · nonDerivative · entry 1 Romano Sarah · CIK 0001697536 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,476 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units ("RSUs"). The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.49 to $1.61. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes unvested RSUs. Read SEC document |
| April 03, 2023 Filed Apr 5, 2023 20:17 UTC | GridAI Technologies Corp. FWBI · Entity 7534 | SaleCommon Stock | 1,975 | $2.50 | $4,937.50 |
DisclosureSEC source: 0001104659-23-042170 · tm2311820-2_4seq1.xml · nonDerivative · entry 1 Romano Sarah · CIK 0001697536 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,453 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units ("RSUs"). The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.41 to $2.60. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes unvested RSUs. F4 · balance_after: All amounts reflect the 1:7 reverse stock split effective as of January 18, 2023 Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 14:01 UTC | GridAI Technologies Corp. FWBI · Entity 7534 | GrantCommon Stock | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-001230 · tm231522-6_4seq1.xml · nonDerivative · entry 1 Romano Sarah · CIK 0001697536 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 F1 · shares: On January 3, 2023, the Reporting Person was granted 150,000 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units vest quarterly for one year with 25% vesting quarterly beginning March 31, 2023. F2 · balance_after: Includes unvested RSUs. Read SEC document |
| March 01, 2022 Filed Mar 2, 2022 23:02 UTC | GridAI Technologies Corp. FWBI · Entity 7534 | GrantStock option (right to buy) · Derivative | 150,000 | $0.00 Strike: $1.18 | $0.00 |
DisclosureSEC source: 0001140361-22-007549 · form4.xml · derivative · entry 1 Romano Sarah · CIK 0001697536 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common stock, par value $0.0001 per share · 150,000 shares Expires 2032-03-01 F1 · derivative.exercise_date: The stock option vests in three equal annual installments commencing on March 1, 2023. Read SEC document |
| February 10, 2022 Filed Feb 11, 2022 21:31 UTC | KIORA PHARMACEUTICALS INC KPRX · Entity 7940 | Tax withholdingCommon Stock | 108 | $0.69 | $74.52 |
DisclosureSEC source: 0001104659-22-020560 · tm226424-1_4seq1.xml · nonDerivative · entry 1 Romano Sarah · CIK 0001697536 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,746 F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 02/01/2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.69 to $0.70, inclusive. The reporting person hereby undertakes to provide to Kiora Pharmaceuticals, Inc., any security holder of Kiora Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| February 01, 2022 Filed Feb 4, 2022 00:06 UTC | KIORA PHARMACEUTICALS INC KPRX · Entity 7940 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $0.77 | $0.00 |
DisclosureSEC source: 0001104659-22-011498 · tm225348d10_4.xml · derivative · entry 1 Romano Sarah · CIK 0001697536 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2032-02-01 F1 · derivative.exercise_date: The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become exercisable as to one-third (1/3) of the shares underlying the Option on February 1, 2023, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years. Read SEC document |
| January 05, 2022 Filed Jan 6, 2022 22:10 UTC | KIORA PHARMACEUTICALS INC KPRX · Entity 7940 | Tax withholdingCommon Stock | 114 | $1.08 | $123.12 |
DisclosureSEC source: 0001104659-22-001943 · tm222161-2_4seq1.xml · nonDerivative · entry 1 Romano Sarah · CIK 0001697536 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,854 F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 01/01/2022. Read SEC document |
| December 07, 2021 Filed Dec 8, 2021 21:15 UTC | KIORA PHARMACEUTICALS INC KPRX · Entity 7940 | Tax withholdingCommon Stock | 91 | $1.30 | $118.30 |
DisclosureSEC source: 0001104659-21-147635 · tm2134911d1_4seq1.xml · nonDerivative · entry 1 Romano Sarah · CIK 0001697536 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,968 F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 12/01/2021. Read SEC document |
| November 02, 2021 Filed Nov 3, 2021 20:15 UTC | KIORA PHARMACEUTICALS INC EYEG · Entity 7940 | Tax withholdingCommon Stock | 83 | $1.98 | $164.34 |
DisclosureSEC source: 0001104659-21-133650 · tm2131814-1_4seq1.xml · nonDerivative · entry 1 Romano Sarah · CIK 0001697536 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,059 F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 11/01/2021. Read SEC document |
| October 04, 2021 Filed Oct 5, 2021 22:40 UTC | KIORA PHARMACEUTICALS INC EYEG · Entity 7940 | Tax withholdingCommon Stock | 83 | $2.01 | $166.83 |
DisclosureSEC source: 0001104659-21-123267 · tm2129310d3_4seq1.xml · nonDerivative · entry 1 Romano Sarah · CIK 0001697536 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,142 F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 10/01/2021. Read SEC document |
| September 02, 2021 Filed Sep 3, 2021 20:16 UTC | KIORA PHARMACEUTICALS INC EYEG · Entity 7940 | Tax withholdingCommon Stock | 84 | $1.81 | $152.04 |
DisclosureSEC source: 0001104659-21-112940 · tm2126978-2_4seq1.xml · nonDerivative · entry 1 Romano Sarah · CIK 0001697536 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,225 F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 09/01/2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.80 to $1.81, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| August 03, 2021 Filed Aug 4, 2021 21:45 UTC | KIORA PHARMACEUTICALS INC EYEG · Entity 7940 | Tax withholdingCommon Stock | 87 | $2.40 | $208.80 |
DisclosureSEC source: 0001104659-21-100196 · tm2124160d1_4seq1.xml · nonDerivative · entry 1 Romano Sarah · CIK 0001697536 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,309 F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 08/01/2021. Read SEC document |
| July 02, 2021 Filed Jul 6, 2021 20:32 UTC | KIORA PHARMACEUTICALS INC EYEG · Entity 7940 | Tax withholdingCommon Stock | 180 | $3.70 | $666.00 |
DisclosureSEC source: 0001104659-21-089447 · tm2121558d4_4.xml · nonDerivative · entry 1 Romano Sarah · CIK 0001697536 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,396 F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 07/01/2021. Read SEC document |
| June 04, 2021 Filed Jun 7, 2021 21:02 UTC | KIORA PHARMACEUTICALS INC EYEG · Entity 7940 | Tax withholdingCommon Stock | 180 | $4.19 | $754.20 |
DisclosureSEC source: 0001104659-21-077765 · tm2119042d3_4seq1.xml · nonDerivative · entry 1 Romano Sarah · CIK 0001697536 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,576 F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 06/01/2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.19 to $4.39, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| May 04, 2021 Filed May 6, 2021 01:57 UTC | KIORA PHARMACEUTICALS INC EYEG · Entity 7940 | Tax withholdingCommon Stock | 177 | $4.13 | $731.01 |
DisclosureSEC source: 0001104659-21-061949 · tm2115347d3_4.xml · nonDerivative · entry 1 Romano Sarah · CIK 0001697536 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,756 F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 05/01/2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.13 to $4.48, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| April 08, 2021 Filed Apr 9, 2021 20:16 UTC | KIORA PHARMACEUTICALS INC EYEG · Entity 7940 | Tax withholdingCommon Stock | 180 | $4.94 | $889.20 |
DisclosureSEC source: 0001104659-21-048715 · tm2112624-3_4seq1.xml · nonDerivative · entry 1 Romano Sarah · CIK 0001697536 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,933 F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 04/01/2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.71 to $4.94, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| March 03, 2021 Filed Mar 5, 2021 21:31 UTC | KIORA PHARMACEUTICALS INC EYEG · Entity 7940 | Tax withholdingCommon Stock | 218 | $5.46 | $1,190.28 |
DisclosureSEC source: 0001104659-21-032766 · tm218853-3_4.xml · nonDerivative · entry 1 Romano Sarah · CIK 0001697536 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,113 F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 03/01/2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.41 to $5.46, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 02:53 UTC | KIORA PHARMACEUTICALS INC EYEG · Entity 7940 | Tax withholdingCommon Stock | 1,282 | $6.34 | $8,127.88 |
DisclosureSEC source: 0001104659-21-011850 · tm215262-8_4seq1.xml · nonDerivative · entry 1 Romano Sarah · CIK 0001697536 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,331 F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 02/01/2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.34 to $6.35, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 02:53 UTC | KIORA PHARMACEUTICALS INC EYEG · Entity 7940 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $6.46 | $0.00 |
DisclosureSEC source: 0001104659-21-011850 · tm215262-8_4seq1.xml · derivative · entry 2 Romano Sarah · CIK 0001697536 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2031-02-01 F3 · derivative.exercise_date: The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become exercisable as to one-third (1/3) of the shares underlying the Option on February 1, 2022, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years. Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 21:16 UTC | KIORA PHARMACEUTICALS INC EYEG · Entity 7940 | Tax withholdingCommon Stock | 115 | $4.85 | $557.75 |
DisclosureSEC source: 0001104659-21-000934 · tm211689-3_4seq1.xml · nonDerivative · entry 1 Romano Sarah · CIK 0001697536 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,613 F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 01/01/2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.84 to $4.85, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| December 07, 2020 Filed Dec 9, 2020 01:16 UTC | KIORA PHARMACEUTICALS INC EYEG · Entity 7940 | Tax withholdingCommon Stock | 91 | $3.76 | $342.16 |
DisclosureSEC source: 0001104659-20-133323 · tm2038041-1_4.xml · nonDerivative · entry 1 Romano Sarah · CIK 0001697536 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,728 F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 12/01/2020. Read SEC document |
| November 02, 2020 Filed Nov 3, 2020 21:15 UTC | KIORA PHARMACEUTICALS INC EYEG · Entity 7940 | Tax withholdingCommon Stock | 97 | $3.51 | $340.47 |
DisclosureSEC source: 0001104659-20-120953 · tm2034888d2_form4.xml · nonDerivative · entry 1 Romano Sarah · CIK 0001697536 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,819 F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 11/01/2020. Read SEC document |
| October 02, 2020 Filed Oct 5, 2020 21:57 UTC | KIORA PHARMACEUTICALS INC EYEG · Entity 7940 | Tax withholdingCommon Stock | 98 | $3.88 | $380.24 |
DisclosureSEC source: 0001104659-20-112301 · tm2032523-2_4.xml · nonDerivative · entry 1 Romano Sarah · CIK 0001697536 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,916 F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 10/01/2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.88 to $3.94, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| September 02, 2020 Filed Sep 3, 2020 21:30 UTC | KIORA PHARMACEUTICALS INC EYEG · Entity 7940 | Tax withholdingCommon Stock | 97 | $3.94 | $382.18 |
DisclosureSEC source: 0001104659-20-102296 · tm2030216d1_form4.xml · nonDerivative · entry 1 Romano Sarah · CIK 0001697536 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,014 F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 09/01/2020. Read SEC document |
| August 04, 2020 Filed Aug 5, 2020 21:12 UTC | KIORA PHARMACEUTICALS INC EYEG · Entity 7940 | Tax withholdingCommon Stock | 95 | $4.11 | $390.45 |
DisclosureSEC source: 0001104659-20-090920 · tm2026743-4_4.xml · nonDerivative · entry 1 Romano Sarah · CIK 0001697536 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,111 F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 08/01/2020. Read SEC document |
| July 02, 2020 Filed Jul 6, 2020 20:15 UTC | KIORA PHARMACEUTICALS INC EYEG · Entity 7940 | Tax withholdingCommon Stock | 97 | $4.82 | $467.54 |
DisclosureSEC source: 0001104659-20-081223 · tm2024119-2_4.xml · nonDerivative · entry 1 Romano Sarah · CIK 0001697536 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,206 F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 07/01/2020. Read SEC document |
| June 03, 2020 Filed Jun 4, 2020 20:17 UTC | KIORA PHARMACEUTICALS INC EYEG · Entity 7940 | Tax withholdingCommon Stock | 94 | $5.11 | $480.34 |
DisclosureSEC source: 0001104659-20-069824 · tm2021837-3_4.xml · nonDerivative · entry 1 Romano Sarah · CIK 0001697536 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,303 F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 06/01/2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.11 to $5.1781, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| May 05, 2020 Filed May 6, 2020 20:31 UTC | KIORA PHARMACEUTICALS INC EYEG · Entity 7940 | Tax withholdingCommon Stock | 93 | $5.10 | $474.30 |
DisclosureSEC source: 0001104659-20-057474 · tm2018856d4_4.xml · nonDerivative · entry 1 Romano Sarah · CIK 0001697536 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,397 F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 05/01/2020. Read SEC document |
| April 02, 2020 Filed Apr 3, 2020 21:54 UTC | KIORA PHARMACEUTICALS INC EYEG · Entity 7940 | Tax withholdingCommon Stock | 122 | $4.97 | $606.34 |
DisclosureSEC source: 0001104659-20-043261 · tm2014998d1_form4.xml · nonDerivative · entry 1 Romano Sarah · CIK 0001697536 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,490 F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 04/01/2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.96 to $5.09, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| March 09, 2020 Filed Mar 10, 2020 23:12 UTC | KIORA PHARMACEUTICALS INC EYEG · Entity 7940 | Tax withholdingCommon Stock | 130 | $5.01 | $651.30 |
DisclosureSEC source: 0001104659-20-031496 · tm2012338d1_4.xml · nonDerivative · entry 1 Romano Sarah · CIK 0001697536 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,612 F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 03/01/2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.00 to $5.07, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| February 14, 2020 Filed Feb 19, 2020 21:32 UTC | KIORA PHARMACEUTICALS INC EYEG · Entity 7940 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001104659-20-022848 · tm209305-8_4.xml · derivative · entry 2 Romano Sarah · CIK 0001697536 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2030-02-14 F2 · derivative.exercise_date: The Reporting Person received an Option to purchase Common Stock from the Issuer pursuant to the Plan. The Option will become exercisable as to one-third (1/3) of the shares underlying the Option on February 1, 2021, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years. Read SEC document |
| February 14, 2020 Filed Feb 19, 2020 21:32 UTC | KIORA PHARMACEUTICALS INC EYEG · Entity 7940 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-022848 · tm209305-8_4.xml · nonDerivative · entry 1 Romano Sarah · CIK 0001697536 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,742 F1 · shares: Grant of restricted stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan (the "Plan"). The restrictions will vest as to one-third (1/3) of the shares on February 1, 2021, and the remaining balance will vest monthly on the first day of each calendar month thereafter for a period of two years. Read SEC document |
| February 04, 2020 Filed Feb 5, 2020 22:00 UTC | KIORA PHARMACEUTICALS INC EYEG · Entity 7940 | Tax withholdingCommon Stock | 109 | $6.00 | $654.00 |
DisclosureSEC source: 0001104659-20-011314 · tm206871d1_4.xml · nonDerivative · entry 1 Romano Sarah · CIK 0001697536 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,742 F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 02/01/2020. Read SEC document |
| January 03, 2020 Filed Jan 6, 2020 22:47 UTC | KIORA PHARMACEUTICALS INC EYEG · Entity 7940 | Tax withholdingCommon Stock | 119 | $9.52 | $1,132.88 |
DisclosureSEC source: 0001104659-20-001637 · tm201302-2_4.xml · nonDerivative · entry 1 Romano Sarah · CIK 0001697536 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,851 F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 01/01/2020 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.3537 to $9.52, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| December 18, 2019 Filed Dec 20, 2019 22:28 UTC | KIORA PHARMACEUTICALS INC EYEG · Entity 7940 | Tax withholdingCommon Stock | 101 | $7.46 | $753.46 |
DisclosureSEC source: 0001104659-19-075136 · tm1926709d4_form4.xml · nonDerivative · entry 1 Romano Sarah · CIK 0001697536 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,970 F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 12/01/2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.46 to $7.53, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| November 05, 2019 Filed Nov 7, 2019 21:15 UTC | KIORA PHARMACEUTICALS INC EYEG · Entity 7940 | Tax withholdingCommon Stock | 108 | $3.85 | $415.80 |
DisclosureSEC source: 0001104659-19-061124 · tm1922166-4_4.xml · nonDerivative · entry 1 Romano Sarah · CIK 0001697536 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,071 F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 11/01/2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.80 to $3.85, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| October 09, 2019 Filed Oct 11, 2019 20:06 UTC | KIORA PHARMACEUTICALS INC EYEG · Entity 7940 | Tax withholdingCommon Stock | 185 | $3.10 | $573.50 |
DisclosureSEC source: 0001144204-19-048123 · tv530956_4.xml · nonDerivative · entry 1 Romano Sarah · CIK 0001697536 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,179 F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 09/01/2019 and 10/01/2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.90 to $3.37, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. F3 · balance_after: Effective as of 08/30/2019, the Issuer effected a 1-for-15 reverse split of its common stock. The number of shares reflects the reverse stock split. Read SEC document |
| August 06, 2019 Filed Aug 7, 2019 23:21 UTC | KIORA PHARMACEUTICALS INC EYEG · Entity 7940 | Tax withholdingCommon Stock | 1,649 | $0.21 | $346.29 |
DisclosureSEC source: 0001144204-19-038334 · tv527077_4.xml · nonDerivative · entry 1 Romano Sarah · CIK 0001697536 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,464 Read SEC document |
| July 15, 2019 Filed Jul 16, 2019 00:39 UTC | KIORA PHARMACEUTICALS INC EYEG · Entity 7940 | SaleCommon Stock | 6,584 | $0.23 | $1,534.07 |
DisclosureSEC source: 0001144204-19-034766 · tv525232_4.xml · nonDerivative · entry 3 Romano Sarah · CIK 0001697536 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 262,113 F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 07/10/2019. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.227 to $0.2403, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form 4. Read SEC document |
| July 12, 2019 Filed Jul 16, 2019 00:39 UTC | KIORA PHARMACEUTICALS INC EYEG · Entity 7940 | SaleCommon Stock | 6,583 | $0.24 | $1,550.95 |
DisclosureSEC source: 0001144204-19-034766 · tv525232_4.xml · nonDerivative · entry 2 Romano Sarah · CIK 0001697536 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,697 F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 07/10/2019. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.2257 to $0.24, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4. Read SEC document |
| July 11, 2019 Filed Jul 16, 2019 00:39 UTC | KIORA PHARMACEUTICALS INC EYEG · Entity 7940 | SaleCommon Stock | 6,583 | $0.24 | $1,583.87 |
DisclosureSEC source: 0001144204-19-034766 · tv525232_4.xml · nonDerivative · entry 1 Romano Sarah · CIK 0001697536 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,280 F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 07/10/2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.24 to $0.245, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.